{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:13Z","timestamp":1792790173702,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ajo.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T02:13:56Z","timestamp":1591755236000},"page":"53-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension"],"prefix":"10.1016","volume":"220","author":[{"given":"Makoto","family":"Aihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghe","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Odani-Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed K.","family":"Shams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2020.06.003_bib1","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"18","key":"10.1016\/j.ajo.2020.06.003_bib2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ajo.2020.06.003_bib3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.06.003_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"9975","key":"10.1016\/j.ajo.2020.06.003_bib5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"issue":"10108","key":"10.1016\/j.ajo.2020.06.003_bib6","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","article-title":"Glaucoma","volume":"390","author":"Jonas","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajo.2020.06.003_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options","volume":"101","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2020.06.003_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"Aqueous humor dynamics: a review","volume":"4","author":"Goel","year":"2010","journal-title":"Open Ophthalmol J"},{"issue":"11","key":"10.1016\/j.ajo.2020.06.003_bib9","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2020.06.003_bib10","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1167\/iovs.03-1176","article-title":"Characterization of uveoscleral outflow in enucleated porcine eyes perfused under constant pressure","volume":"45","author":"Wagner","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2020.06.003_bib11","series-title":"Asia-Pacific Glaucoma Guidelines","year":"2016"},{"issue":"1","key":"10.1016\/j.ajo.2020.06.003_bib12","first-page":"P41\u2212P111","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2020.06.003_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2147\/OPTH.S13884","article-title":"Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs","volume":"4","author":"Schmier","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2020.06.003_bib14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/eye.2012.195","article-title":"Adverse periocular reactions to five types of prostaglandin analogs","volume":"26","author":"Inoue","year":"2012","journal-title":"Eye Lond"},{"key":"10.1016\/j.ajo.2020.06.003_bib15","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2020.06.003_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/jop.2014.0067","article-title":"Pharmacotherapy of glaucoma","volume":"31","author":"Schmidl","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ajo.2020.06.003_bib17","doi-asserted-by":"crossref","first-page":"e0181550","DOI":"10.1371\/journal.pone.0181550","article-title":"Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy","volume":"12","author":"Miki","year":"2017","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ajo.2020.06.003_bib19","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.1021\/acs.jmedchem.8b00808","article-title":"Identification of a selective, non-prostanoid EP2 receptor agonist for the treatment of glaucoma: omidenepag and its prodrug omidenepag isopropyl","volume":"61","author":"Iwamura","year":"2018","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.ajo.2020.06.003_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1167\/iovs.17-22745","article-title":"Pharmacologic characterization of omidenepag isopropyl, a novel selective EP2 receptor agonist, as an ocular hypotensive agent","volume":"59","author":"Kirihara","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2020.06.003_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/jop.2017.0146","article-title":"Effects of a novel selective EP2 receptor agonist, omidenepag isopropyl, on aqueous humor dynamics in laser-induced ocular hypertensive monkeys","volume":"34","author":"Fuwa","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.ajo.2020.06.003_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/IJG.0000000000001221","article-title":"Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Aihara","year":"2019","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.ajo.2020.06.003_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2020.06.003_bib24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2020.06.003_bib25","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/j.ophtha.2009.08.014","article-title":"Tonometer calibration","volume":"116","author":"Kumar","year":"2009","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2020.06.003_bib26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archopht.1996.01100140137004","article-title":"A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study","volume":"114","author":"Mishima","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2020.06.003_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0021-5155(99)00147-1","article-title":"Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan","volume":"44","author":"Suzuki","year":"2000","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2020.06.003_bib28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41467-017-01913-6","article-title":"A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure","volume":"8","author":"Choquet","year":"2017","journal-title":"Nat Commun"},{"issue":"Suppl. 1","key":"10.1016\/j.ajo.2020.06.003_bib29","first-page":"S19","article-title":"A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure","volume":"499","author":"Choplin","year":"2004","journal-title":"Semin Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2020.06.003_bib30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archopht.1991.01080080050026","article-title":"Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey","volume":"109","author":"Sommer","year":"1991","journal-title":"Arch Ophthalmol"},{"issue":"Suppl. 1","key":"10.1016\/j.ajo.2020.06.003_bib31","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side effects associated with prostaglandin analog therapy","volume":"53","author":"Alm","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2020.06.003_bib38","first-page":"741","article-title":"Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension","volume":"4","author":"Lee","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2020.06.003_bib39","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2020.06.003_bib40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/02713683.2011.593725","article-title":"A Phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension","volume":"36","author":"Schachar","year":"2011","journal-title":"Curr Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2020.06.003_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00003226-200107000-00008","article-title":"Diurnal variation of corneal and corneal epithelial thickness measured using optical coherence tomography","volume":"20","author":"Feng","year":"2001","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2020.06.003_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1034\/j.1600-0420.1998.760114.x","article-title":"Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility","volume":"76","author":"Kaminski","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"issue":"10","key":"10.1016\/j.ajo.2020.06.003_bib43","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archopht.1993.01090100051026","article-title":"Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor","volume":"111","author":"Wilkerson","year":"1993","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2020.06.003_bib44","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ophtha.2009.03.024","article-title":"Corneal thickness and glaucoma medications","volume":"116","author":"Mehdizadeh","year":"2009","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2020.06.003_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/IJG.0b013e31815d784c","article-title":"Comparison of the effects of latanoprost and bimatoprost on central corneal thickness","volume":"17","author":"Sen","year":"2008","journal-title":"J Glaucoma"},{"issue":"5","key":"10.1016\/j.ajo.2020.06.003_bib46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/jop.2013.0196","article-title":"Effects of long-term topical prostaglandin therapy on central corneal thickness","volume":"30","author":"Maruyama","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2020.06.003_bib47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bjophthalmol-2016-308432","article-title":"The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma","volume":"101","author":"Meda","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2020.06.003_bib48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archopht.117.6.794","article-title":"Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway","volume":"117","author":"Sagara","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2020.06.003_bib49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/02713680591006237","article-title":"Effect of latanoprost on cultured porcine corneal stromal cells","volume":"30","author":"Wu","year":"2005","journal-title":"Curr Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2020.06.003_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0039-6257(00)00110-7","article-title":"Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach","volume":"44","author":"Doughty","year":"2000","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2020.06.003_bib51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ajo.2008.05.048","article-title":"Intraocular pressure, central corneal thickness, and prevalence of open-angle glaucoma: the Los Angeles Latino Eye study","volume":"146","author":"Francis","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2020.06.003_bib52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/jop.2019.0044","article-title":"Pharmacokinetics, safety and IOP lowering profiles of omidenepag isopropyl, a selective EP2 agonist in healthy Japanese and Caucasian volunteers (Phase I study)","volume":"35","author":"Aihara","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ajo.2020.06.003_bib53","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1167\/iovs.08-2843","article-title":"The glaucoma research community and FDA look to the future: a report from the NEI\/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium","volume":"50","author":"Weinreb","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"}],"updated-by":[{"DOI":"10.1016\/j.ajo.2021.03.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420302889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939420302889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T01:13:33Z","timestamp":1668561213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939420302889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":46,"alternative-id":["S0002939420302889"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2020.06.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738139245.793575647","asserted-by":"object"}]},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}